The stock's rise snapped a four-day losing streak.

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Illumina (ILMN). But which of these two stocks is more attractive to value ...

The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.

In a report released yesterday, Conor McNamara from RBC Capital maintained a Buy rating on Illumina (ILMN – Research Report), with a price ...

Illumina slashes costs by $100 million after China bans its sequencers. The company lowers its 2025 EPS outlook and aims for ...

TD Cowen analyst Daniel Brennan maintained a Hold rating on Illumina (ILMN – Research Report) today and set a price target of $140.00. The ...

Illumina lowered its adjusted profit outlook and cut spending cost for 2025 as the company grapples with Chinese ban on its ...

Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban ...

We recently published an article titled Why These 15 Large-Cap Stocks Are Plunging So Far In 2025. In this article, we are ...

What a brutal six months it’s been for Illumina. The stock has dropped 30.9% and now trades at $84.65, rattling many shareholders. This may have investors wondering how to approach the situation.

The Africa Centres for Disease Control and Prevention (Africa CDC) and Illumina (NASDAQ: ILMN), a global leader in sequencing ...

The stock's fall snapped a two-day winning streak.